je.st
news
Tag: gileads
Pharmacy giant CVS opts to exclusively offer Gilead's pricey hepatitis C drug
2015-01-05 21:32:29| Biotech - Topix.net
Gilead Sciences Inc. , whose stock plummeted last month when Express Scripts Holding Co. chose to offer a competitor's hepatitis C drug, jumped Monday after CVS Health Corp. said Gilead's pill would be offered exclusively to patients on its drug benefit plans.
Tags: offer
drug
giant
exclusively
Biotech Investors bail out after Gilead's drug pricing fight
2014-12-24 00:59:28| Biotech - Topix.net
The biotechnology sector is having its worst day since April as investors fear health insurers and companies that manage patient's drug benefits will put new pressure on how much the industry can charge for breakthrough treatments. The selloff, prompted by Express Scripts Holding's announcement Monday that it would block its U.S. patients from getting Gilead Sciences's $1,100-a-pill hepatitis C medicine, sent the Nasdaq Biotechnology Index down 4.6 percent, the biggest one-day drop since April.
Tags: drug
fight
pricing
investors
European Commission Grants Marketing Authorization for Gilead's...
2014-11-19 12:58:48| Biotech - Topix.net
Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Harvoni , the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir , approved by the European Commission under the tradename Sovaldi in January 2014.
Tags: marketing
european
commission
grants
Sub-Optimal 39% Hep C Cure Rate Keeps Merck In Gilead's Rear View
2014-11-13 14:42:27| Biotech - Topix.net
Until Merck's product can deliver an optimal cure rate at a cheaper price, it poses no threat to Gilead's Harvoni. Merck's attempt to compete with Gilead in finding a cure for hepatitis C has fallen short .
Gilead's $1,000-a-pill hepatitis C drug may make financial sense for prisons
2014-10-21 15:36:50| Biotech - Topix.net
Sovaldi's $1,000-a-pill price has grabbed headlines, but a new study suggests it may actually be cost effective for prison systems. Pricey new hepatitis C drugs, such as Gilead Sciences Inc.'s Sovaldi, may make financial sense to give to give to prisoners, one of the main groups infected with the liver-damaging virus, according to a team of Stanford University researchers.
Tags: make
financial
sense
drug